SCHEDULE: BioStar Ventures Cuts Autonomix Medical Stake

Sentiment:

Beneficial Ownership Update 14 August 2025 4:37 PM

BioStar Ventures III, L.P. and its general partner have reduced their beneficial ownership in Autonomix Medical, Inc. to 4.3% of common stock.

Worse than expectedBioStar Ventures III, L.P. and BioStar Ventures III, L.L.C. have reduced their beneficial ownership in Autonomix Medical, Inc. to 4.3%, indicating a decrease from a previous stake that would have triggered an initial Schedule 13G filing (i.e., greater than 5%). This reduction by a significant investor can be perceived negatively by the market.

Summary

BioStar Ventures III, L.P. and BioStar Ventures III, L.L.C. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Autonomix Medical, Inc.
The Reporting Persons collectively beneficially own 175,216 shares of Autonomix Medical, Inc. common stock.
This ownership represents 4.3% of the outstanding common stock of Autonomix Medical, Inc.
The beneficial ownership includes 120,816 shares of common stock directly held by BioStar III and warrants exercisable for an additional 54,400 shares of common stock.
The percentage is calculated based on 4,022,625 shares of common stock outstanding as of June 30, 2025, as reported in the Issuer's Form 10-Q filed on August 13, 2025, adjusted for exercisable warrants.

Sentiment

Score: 3

Explanation: The sentiment is slightly negative as a significant investor has reduced their stake below the 5% threshold, which could signal a lack of confidence or a strategic reallocation of capital.

Negatives

The filing indicates a reduction in beneficial ownership by BioStar Ventures III, L.P. and BioStar Ventures III, L.L.C. to below the 5% threshold, suggesting a decrease from a previously higher stake that triggered an initial Schedule 13G filing.

Future Outlook

Industry Context

This filing is a standard disclosure of beneficial ownership and does not provide broader industry context or trends.

Stakeholder Impact

Shareholders may view the reduction in stake by a notable institutional investor as a negative signal regarding the company's future prospects or valuation.

Key Dates

Date	Description
06/30/2025	Date of event which required the filing of this statement (beneficial ownership calculation date).
08/13/2025	Date Autonomix Medical, Inc. filed its Quarterly Report on Form 10-Q, providing the basis for shares outstanding.
08/14/2025	Date of signing and filing of this Schedule 13G Amendment.

Recommendation

hold

The reduction in beneficial ownership by BioStar Ventures III, L.P. and BioStar Ventures III, L.L.C. to 4.3% from a previously higher stake is a negative signal. While not a catastrophic event, it warrants caution as a significant investor has reduced their exposure. Investors should hold and monitor for further developments or other signals from the company's operational performance or strategic direction.

Keywords

Autonomix Medical, BioStar Ventures, Schedule 13G, beneficial ownership, common stock, investment, medical device

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.